Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.16M Sell
9,912
-475
-5% -$105K 0.16% 59
2025
Q4
$2.37M Buy
10,387
+126
+1% +$28.7K 0.17% 55
2025
Q3
$2.38M Buy
10,261
+415
+4% +$84.5K 0.17% 50
2025
Q2
$1.83M Sell
9,846
-1,802
-15% -$335K 0.15% 67
2025
Q1
$2.44M Buy
11,648
+134
+1% +$26.1K 0.22% 46
2024
Q4
$2.05M Sell
11,514
-16
-0.1% -$2.94K 0.18% 54
2024
Q3
$2.28M Buy
11,530
+3
+0% +$560 0.2% 51
2024
Q2
$1.98M Buy
+11,527
New +$1.91M 0.2% 50

Other funds holding ABBV

Hardy Reed's ABBV Position: Q1 2026 in Review

Hardy Reed reduced its AbbVie (ABBV) stake by 4.6% in Q1 2026, selling an estimated $105K and leaving 9,912 shares worth $2.16M. The position accounts for 0.16% of the portfolio, ranked #59.

Hardy Reed first reported a position in ABBV in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.44M in Q1 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Hardy Reed held 9,912 shares of AbbVie worth $2.16M as of Q1 2026.
  • Hardy Reed sold 475 AbbVie shares in Q1 2026, an estimated $105K.
  • AbbVie made up 0.16% of Hardy Reed's portfolio in Q1 2026, its #59 holding.
  • Hardy Reed first reported a position in AbbVie in Q2 2024 and has held it in 8 quarters since.
  • Hardy Reed's AbbVie position peaked at $2.44M in Q1 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hardy Reed's 13F filing for Q1 2026, filed 28 Apr 2026.